# Dreisam

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/dreisam

- Industry: Medical Devices & Equipment
- Headquarters: Beijing, China
- Website: www.dreisamtech.com
- Latest round: Series A (Mar 12, 2026)
- Investors on record: 4

## About

Dreisam (Beijing) Medical Tech focuses on advancing technology solutions, specializing in software and hardware products that enhance operational efficiency and productivity for various industries.Dreisam (Beijing) Medical Tech, founded in 2020 in Beijing, China, develops innovative technology solutions tailored for operational efficiency. The company has completed 4 significant deals since its inception, with the latest funding round occurring on March 12, 2026. The firm has not undergone any noted pivots or changes in its operational strategy.Dreisam specializes in advanced technology solutions, primarily offering software applications that streamline data management, analytics, and automation. Their products target inefficiencies in data handling and communication, catering to diverse clients from small businesses to large corporations across sectors like manufacturing, logistics, and finance. The company's solutions are marketed in key regions, including North America, Europe, and parts of Asia, responding to the growing demand for digital transformation.Dreisam generates revenue through direct sales and subscription-based models for its software solutions. The company primarily engages in B2B transactions, providing corporate clients with robust tools for data analysis and management. Pricing plans include tiered subscriptions based on user numbers or data volume, with bespoke services offered to enhance customer experience. Their flagship products contribute significantly to the company's revenue, reinforcing its position in the technology landscape.Dreisam aims to expand its product line with upcoming launches in 2026, focusing on new software solutions that enhance data processing capabilities. The company plans to penetrate new markets in Southeast Asia and Eastern Europe by late 2026. The recent Series A+ funding raised in March 2026 from Addor Capital will support these initiatives, enabling Dreisam to bolster its product development and market outreach.

## Funding rounds

- Series A, Mar 12, 2026 — Addor Capital
- Series A, Oct 26, 2021 — China Growth Capital, IMEik
- Angel, Jul 1, 2020 — Chang'an Capital

## Investors

- Chang'an Capital (https://capitalatlas.ai/funds/chang-an-capital) — Angel
- China Growth Capital (https://capitalatlas.ai/funds/china-growth-capital) — Series A
- IMEik — Series A
- Addor Capital (https://capitalatlas.ai/funds/addor-capital) — Series A